MARKET

DMAC

DMAC

DIAMEDICA THERAPEUTICS INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.04
+0.23
+2.34%
After Hours: 10.05 +0.01 +0.10% 17:39 01/15 EST
OPEN
9.95
PREV CLOSE
9.81
HIGH
10.05
LOW
9.45
VOLUME
188.59K
TURNOVER
--
52 WEEK HIGH
10.52
52 WEEK LOW
1.870
MARKET CAP
188.14M
P/E (TTM)
-13.2471
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
DiaMedica Therapeutics to Present at the H.C. Wainwright BioConnect Conference
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for neurological and kidney diseases, today announced that it will be presenting at the H.C. Wainwright BioConnect 2021 Conference, being hel...
Business Wire · 01/11 13:00
Here's Why We're Not At All Concerned With DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 01/09 07:32
The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 4)
Benzinga · 01/05 13:38
DiaMedica Therapeutics Announces Enrollment Of Last Patient In Diabetic Kidney Disease Cohort Of Phase 2 REDUX CKD Study
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) today announced that the last participant has been enrolled and is on treatment in the diabetic kidney disease Cohort of the Company's Phase 2 REDUX chronic kidney disease
Benzinga · 12/15/2020 13:10
DiaMedica Therapeutics Announces Enrollment of Last Patient in Diabetic Kidney Disease Cohort of Phase 2 REDUX CKD Study
Business Wire · 12/15/2020 13:04
Is DMAC A Good Stock To Buy Now?
In this article we will take a look at whether hedge funds think DiaMedica Therapeutics Inc. (NASDAQ:DMAC) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend milli...
Insider Monkey · 12/11/2020 02:24
DiaMedica rises 6% on successful Type B meeting with FDA for DM199 study in acute ischemic stroke
DiaMedica Therapeutics (DMAC) has recently received responses from the FDA following a Type B Pre-IND meeting request, submitted in October 2020 regarding the development plan for its product candidate, DM199,
Seekingalpha · 12/10/2020 13:40
DiaMedica Therapeutics Announces Successful Type B Meeting With FDA For Study Of DM199 In Patients With Acute Ischemic Stroke; Co. Plans To Submit IND Application For Phase 2/3 Study In Q1 Of 2021
DiaMedica Plans to Submit an Investigational New Drug (IND) Application with to FDA for a Phase 2/3 Study in the First Quarter of 2021 DiaMedica Therapeutics Inc. (NASDAQ:DMAC) announced that it recently
Benzinga · 12/10/2020 13:06
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DMAC. Analyze the recent business situations of DIAMEDICA THERAPEUTICS INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average DMAC stock price target is 16.20 with a high estimate of 28.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 40
Institutional Holdings: 7.19M
% Owned: 38.35%
Shares Outstanding: 18.74M
TypeInstitutionsShares
Increased
12
1.53M
New
15
2.15M
Decreased
2
9.44K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/Director
Richard Pilnik
President/Chief Executive Officer/Director
Rick Pauls
Chief Financial Officer/Secretary
Scott Kellen
Vice President
Sydney Gilman
Vice President - Business Development
Paul Papi
Director
Harry Alcorn
Director
James Parsons
Director
Jerry Xiao
Independent Director
Michael Giuffre
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company primarily focused on the development of recombinant (synthetic) proteins. The Company uses its technologies for the development and commercialization of recombinant proteins to treat kidney and neurological diseases. The Company’s focus is on chronic kidney disease (CKD) and acute ischemic stroke (AIS). The Company’s lead product DM199, is a drug candidate, a commercial potential as a therapy for CKD and AIS. DM199 is a recombinant form of human tissue kallikrein-1 (KLK1). KLK1 is a serine protease (protein) produced primarily in the kidneys, pancreas and salivary glands that plays a critical role in the regulation of local blood flow and vasodilation (the widening of blood vessels, which decreases vascular resistance) in the body, as well as an important role in inflammation and oxidative stress.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of DiaMedica Therapeutics Inc stock information, including NASDAQ:DMAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMAC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DMAC stock methods without spending real money on the virtual paper trading platform.